28.3 C
Vientiane
Tuesday, May 20, 2025
spot_img
Home Blog Page 459

APAC Hiring Intentions Strengthen as Employers Express Optimism for Q2 2025

  • The Net Employment Outlook for Q2 2025 in Asia Pacific is 30%, up 3 points from both Q1 2025 and Q2 2024.
  • Employers in India (+43%), mainland China (+32%) and Singapore (+27%) report the strongest Outlooks in the region, while Hong Kong SAR shows the most cautious Outlook (+11%).
  • The Information Technology sector continues to lead hiring intentions (+42%), followed by Financials & Real Estate (+34%) and Industrials and Materials (+31%).
  • Larger organizations demonstrate the strongest hiring intentions, with companies of 5,000+ employees reporting the strongest Outlook (+38%).

SINGAPORE, March 11, 2025 /PRNewswire/ — The latest ManpowerGroup Employment Outlook Survey reveals a strengthened hiring Outlook across the Asia Pacific (APAC) region for Q2 2025, with a Net Employment Outlook (NEO) of 30%. This represents an increase of 3 points compared to both the previous quarter and Q2 2024.

Q2 2025 ManpowerGroup Employment Outlook Survey - APAC Key Findings
Q2 2025 ManpowerGroup Employment Outlook Survey – APAC Key Findings

The Survey, which gathered data from over 10,078 employers across seven APAC countries and territories, indicates a growing confidence in the region’s labor market as businesses look to expand and invest in talent.

“The latest uptick in hiring intentions across APAC is a promising sign for the market. When compared to the previous quarter, the increased hiring intentions employers are reporting this quarter reflect the region’s adaptability and persistent focus on growth,” said François Lançon, Regional President, Asia Pacific & Middle East.

Besides employment Outlooks, the APAC report also shed light on the main reasons for staffing increases. 42% of employers in APAC report company expansion as the top reason for staffing increases, followed by new ventures requiring new roles (33%), and tech advancements needing more expertise (31%).

“Companies across APAC are proactively shaping their workforce for long-term growth and innovation. The focus on technology and expansion reflects a strategic pivot to future-proof businesses, ensuring competitiveness in a rapidly evolving global landscape. Initiatives like mainland China’s AI investment fund, Hong Kong’s investment in an AI Research and Development Institute, and Singapore’s New Enterprise Compute Initiative are fueling demand for skilled talent, particularly in tech and AI. These efforts underscore the region’s drive toward technological leadership, even amid economic challenges, solidifying APAC’s position as a hub of resilience and opportunity,” Mr Lançon said.

To view the complete results for the Q2 2025 ManpowerGroup Employment Outlook Survey, including regional and country data, visit: www.manpowergroup.com.sg/meos-apac.

Magcubic Disrupts the Smart Projector Market with Affordable Products for Everyone

BEIJING, March 11, 2025 /PRNewswire/ — Smart projectors can transform virtually any wall into a smart display, but their expensive price tags make them unrealistic for most buyers. Magcubic set out to revolutionize the projector market with the HY300 Pro in 2024, and now we’re back with the expanded HY300 lineup – led by the brand new HY300 Pro+, HY300 Ultra, and HY310 – that offers premium-quality hardware and an exceptional user experience in a series of ultra-affordable projectors.

Magcubic was created to challenge the status quo of conventional smart projectors. We started with a mission to make big-screen experiences accessible to a wider range of users, and we followed that by releasing a lineup of full-featured projectors that deliver a cinematic experience once priced at $1,000—now available for less than $100. Today, we’ve shipped 2 million units worldwide, an industry milestone that was once impossible on a global scale.

Unveiled in Beijing on March 9th with 100+ Chinese media outlets in attendance, the new HY300 series is available today in three versions, starting with the HY300 Pro, an entry-level projector designed with affordability and ease-of-use in mind. Next is the HY300 Pro+, an upgraded version featuring enhanced performance and an integrated speaker base for better audio playback. Third is the HY300 Ultra, an even more enhanced variant with electric focus, ensuring effortless image clarity. 

Alongside the expanded HY300 range is a brand new next-generation model called the HY310. This projector was crafted from the ground up to encompass a range of features designed to thrill cinema enthusiasts, including clear 1080p resolution with 4K decoding for crisp video performance, auto focus with auto keystone correction that ensures a sharp image every time the projector powers on, 260 ANSI lumens with a 10,000:1 contrast ratio for a bright picture that’s viewable in various lighting conditions, Air Mouse remote and voice controls for easy navigation, and built-in support for 1M+ apps, services, and entertainment options so that viewers always have something to watch.

The secret to keeping our ecosystem of high-quality projectors affordable – even with so many premium features packed inside – is our LCD technology, which uses liquid crystals that are electronically modulated in combination with polarizers to project images on a surface. While competitors choose pricey LEDs to prop up their products, Magcubic prioritizes proven liquid crystal display bulbs that produce premium visuals without inflating costs. To further drive down the price of our smart projectors, Magcubic’s proprietary manufacturing process is so efficient and effective that we’ve lowered our expenses by a whopping 80%. The end result is an entire series of premium smart projectors that rival more expensive DLP models at just a fraction of the typical price.

“We are redefining value by creating a unique convergence where spending less meets living better,” said Chen Yueyun, the General Manager of Magcubic. 

Today, Magcubic operates in 153 countries worldwide, with a growing presence in the United States. Driven by a product ecosystem that maximizes affordability while emphasizing quality and user experience, Magcubic believes that smart projectors will move beyond the niche market and become household commodities with the potential to surpass smart TVs.

ABOUT MAGCUBIC

Magcubic was founded by tech and home entertainment experts on a mission to bring big-screen experiences worldwide. Seeing the need for smart projectors that are well-made and affordable, we set out to disrupt the industry. Through premium materials and innovative manufacturing, we deliver high-quality products that save consumers money and delight users.

For media enquiries, please contact: 
ALICE ZHANG
Email: marketing@magcubic.com

Macronix OctaFlash Provides High-Performance Memory for New STMicroelectronics’ STM32N6 AI-Accelerated MCU Platform

1Gb OctaFlash™ Memory Helps Enable Advanced AI Applications, 3D-like GUI Experience

HSINCHU, March 11, 2025 /PRNewswire/ — Macronix International Co., Ltd. (TSE: 2337), a leading integrated device manufacturer in the non-volatile memory (NVM) market and an ST Authorized Partner, today announced that STMicroelectronics (ST) is using Macronix OctaFlash™ memory for ST’s new STM32N6 high-performance microcontroller (MCU) platform integrating the high performance Neural Processing Unit (NPU), the Neural-ART AcceleratorTM. Macronix’s MX25UW1G45G and MX25UM51245G memories have been selected by ST for STM32N6 Discovery Kits and STM32N6 Nucleo evaluation boards, enabling the high-end designs to feature high-performance flash memory, enabling powerful artificial intelligence (AI) computer-vision applicability and a graphical user interface (GUI) experience that simulates 3D-like GUIs and animations for industrial, wearable, smart home, and medical applications.

“Neural processing presents an exciting opportunity for the STM32N6 and future ST microcontrollers, which we expect to see deployed throughout the industrial and consumer markets,” said Daniel Colonna, marketing director of the General Purpose and Automotive Microcontrollers Division at ST. “To ensure designers have the optimal tools to create products using the STM32N6 and high-performance flash memory, we have selected Macronix’s OctaFlash MX25UW1G45G and MX25UM51245G for the STM32N6 Discovery Kits” and “Macronix is a proven global supplier of industry-leading flash memory and a longtime ST Authorized Partner, which made the selection straightforward for us.”

“The STM32N6 represents an exciting new generation of high-performance microcontrollers for neural processing in artificial intelligence deployed on systems’ edges,” said F.L. Ni, vice president of marketing at Macronix. “That ST selected our MX25UW1G45G and MX25UM51245G high-performance flash devices stands as a testament to the memories’ exceptional performance and security, and ST’s commitment to high optimal reliability and user experience in such demanding applications.”

The STM32N6 is based on the Arm® Cortex®-M55 processing core, running at 800 MHz and includes Arm Helium vector technology. It’s the first STM32 MCU to embed the Neural-ART accelerator, an ST-developed neural processing unit (NPU) engineered for power-efficient edge AI applications. Clocked at 1 GHz and providing up to 600 GOPS, it enables real-time neural network inference for computer vision and audio applications.

The MX25UM/UW OctaFlash memories deliver “instant-on” performance and real-time system responsiveness in automotive, industrial and consumer applications, including AI. The ultra-high-performance OctaBus™ memory are capable of performing up to an operational frequency of and industry-leading 250MHz with 500MB/s read throughput. The MX25UM/UW OctaFlash empowers system architects to satisfy customers’ demands in high performance AI applications, such as computer vision and rich graphical user interfaces.

The MX25UM/UW OctaBus memory family supports efficient Execution-In-Place (XIP), management of over-the-air (OTA) software updates and data logging – features that complement STM32 MCUs well. MX25UM/UW memories are available in densities up to 2Gb and can support the most advanced AI and graphical user interfaces that leverage on the accelerators embedded in STM32N6.

About Macronix 
Macronix, a leading integrated device manufacturer in the non-volatile memory (NVM) market, provides a full range of NOR Flash, NAND Flash, and ROM products. With its world-class R&D and manufacturing capability, Macronix continues to deliver high-quality, innovative and performance-driven products to its customers in the consumer, communication, computing, automotive, networking and other market segments. Find out more at www.macronix.com.

OctaFlash and OctaBus are trademarks of Macronix International Co., Ltd. 
Neural-ART Accelerator is a trademark of STMicroelectronics.
STM32 is a registered and/or unregistered trademark of STMicroelectronics International NV or its affiliates in the EU and/or elsewhere. In particular, STM32 is registered in the US Patent and Trademark Office.

All other names may be registered trademarks of their respective owners.

Editorial contacts
Macronix HQ:
Michelle Chang
Director
Corporate Communication Office
Macronix International Co., LTD.
Tel: +886-3-578-6688 ext. 71233
Fax: +886-3-666-3169
Email: michellechang@mxic.com.tw

US:
Jerry Steach
CommonGround Communications (for Macronix)
Tel: +1-415-222-9996
Email: jsteach-cgc@att.net

Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity

BEIJING and BRIDGEWATER, N.J., March 10, 2025 /PRNewswire/ — Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced that the first participant has been successfully dosed in a Phase 2 clinical trial of bofanglutide (research code: GZR18) injection, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) independently developed by Gan & Lee, in the US participants with overweight or obesity. Notably, bofanglutide is the first GLP-1 receptor mono-agonist to undergo a head-to-head comparison with tirzepatide for evaluating the efficacy in body weight management globally.

This Phase 2 clinical trial (ClinicalTrials.gov registration number: NCT06737042) was designed to evaluate the efficacy and safety of bofanglutide injection in US adults with overweight or obesity. The study plans to enroll 285 subjects, who will be randomized to receive either 24 mg, 36 mg, or 48 mg of bofanglutide bi-weekly, 15 mg of tirzepatide once-weekly, or placebo. The primary endpoint is the percentage change in body weight from baseline at the end of the treatment.

Previously, a Phase 1 study (NCT06548997) of bofanglutide injection demonstrated good safety and tolerability in US subjects, along with promising glucose-lowering and weight-loss potential[1]. The initiation of head-to-head clinical study for bofanglutide versus tirzepatide, marking a new phase in Gan & Lee’s GLP-1 innovation. This milestone underscores the company’s ambition to challenge the leading GLP-1 therapy in the global market for weight management, aiming to provide a better treatment option for patients with overweight or obesity worldwide.

Reference:

[1].Liu Y, Chen W, He X, He A, Zhao L, Xie T, Li Y, Zhao J, Hunt A, Shi A, Gan ZR. The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects. Diabetes Obes Metab. 2025 Mar 3. doi: 10.1111/dom.16285. Epub ahead of print. PMID: 40028667.

About Bofanglutide (GZR18)

Bofanglutide (R&D Code: GZR18) injection, developed by Gan & Lee Pharmaceuticals, is a bi-weekly GLP-1 receptor agonist (RA) indicated for glycemic control in adults with type 2 diabetes and body weight management in overweight/obese individuals. As the potential first bi-weekly GLP-1 RA in the world, early clinical trials have demonstrated its efficacy in weight reduction comparable to or superior to marketed counterparts, with a safety and tolerability profile consistent with the established class of GLP-1 RAs, and significant reductions in both blood glucose levels and body weight.

Forward-looking statements

Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin), fast-acting lispro injection (Prandilin®™), fast-acting aspart injection (Rapilin), mixed protamine zinc lispro injection (25R) (Prandilin®™25), aspart 30 injection (Rapilin30), and one human insulin injection – mixed protamine human insulin injection (30R) (Similin30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine)®.

In China’s 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets®.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.

Movement Network Foundation Announces Public Mainnet Beta Now Live with $250M+ TVL

Innovative day-one liquidity fuels the latest Move blockchain network launch

GRAND CAYMAN, Cayman Islands, March 10, 2025 /PRNewswire/ — The Movement Network Foundation, the organization dedicated to advancing MoveVM technology, today announced the successful launch of Movement Public Mainnet Beta, with an impressive $250M in at-launch Total Value Locked (TVL) from the Cornucopia program. This milestone enables permissionless smart contract deployment and user onboarding for the first time and allows everyone to freely build on and use Movement, the only Move-based chain that settles to Ethereum.

Cornucopia Deepens Liquidity

“Securing over $233 million in TVL through our Cornucopia program is a clear validation of the market’s confidence in Movement,” said Cooper Scanlon, Co-Founder of Movement Labs. “This level of day-one liquidity is exceptionally rare for a new network and gives us, our builders, and our community a significant advantage. It allows us to skip the months-long bootstrapping phase and immediately provide the foundation needed for meaningful DeFi adoption and utility.”

Cornucopia provides Movement Network with substantial day-one liquidity across BTC, ETH, MOVE, and stablecoin assets, addressing one of the primary challenges new networks face: the “cold start” problem. Developed with industry leaders including Concrete, Veda Labs, Echelon and Canopy, this robust financial foundation enables Movement to support sophisticated DeFi applications from day one.

Public Mainnet Beta Launch: Features

Movement Network is a secure and scalable network of Move-based chains secured by Ethereum, creating safer execution environments through the Move programming language originally developed by Meta to power safer, better digital economies. Movement is the Network’s first chain.

Public Mainnet Beta key features:

  • Permissionless smart contract deployment
  • Full user onboarding and engagement
  • Attestations of block states will be committed to Ethereum as part of the Movement’s Fast Finality Settlement.
  • Canonical Movement bridge via LayerZero

“With Public Mainnet Beta, developers can now deploy smart contracts without approval, and users can freely engage with the Movement ecosystem. This marks the beginning of a new chapter for Move-based technology, combining robust security and better performance with Ethereum’s network affects” added Rushi Manche, Co-Founder, Movement Labs.

The launch features the canonical Movement bridge powered by LayerZero, enabling users to seamlessly transfer MOVE (the network’s native gas token), USDT, USDC, wBTC, wETH, and more to the Movement chain.

The Movement Network Foundation will continue to launch additional features over time as the ecosystem evolves.

For more information about Movement Public Mainnet Beta, For more information about Movement’s Developer Mainnet, visit movementnetwork.xyz or follow @movementlabsxyz, @movementfdn, @moveecosystem @Move_Collective on Twitter.

About Movement Network Foundation
Movement Network Foundation is the driving force behind the Movement ecosystem, dedicated to fostering innovation and advancing the adoption of MoveVM technology. The foundation oversees the development of Movement Network, a next-gen solution built using MoveVM that settles to Ethereum. Through its MoveDrop program and ecosystem initiatives, the foundation supports developers, projects, and community contributors building decentralized applications. Learn more at movementfdn.xyz or follow @movementfdn on X.

MEDIA CONTACT:
Carmen Pearson
Head of PR & Communications
Movement Labs
Carmen.Pearson@MovementLabs.xyz

 

70mai Unveils 4K Omni: The Ultimate 360° Dash Cam for Unmatched Protection

SHANGHAI, March 10, 2025 /PRNewswire/ — 70mai, a leading innovator in dash cam technology, introduces the 70mai 4K Omni, an advanced upgrade to the world’s first 360° rotating dash cam, delivering comprehensive protection in any driving scenario. Now equipped with dual-channel recording, it pairs a 4K Sony STARVIS 2 front camera with a 1080P HDR rear camera, ensuring seamless 360° coverage. With 4K 60FPS recording, every detail is captured with cinematic precision, even at high speeds.

70mai 4K Omni
70mai 4K Omni

Whether navigating city streets or parking in low-light conditions, the 4K Omni delivers superior imaging. MaiColor Vivid+ Solution™ enhances brightness and clarity, while windshield color compensation reduces glare for crystal-clear visuals. 70mai Night Owl Vision™ enhances nighttime visibility, while 70mai Lumi Vision ensures reliable footage even in near-total darkness.

For round-the-clock vehicle security, the 24-Hour Smart Parking Surveillance system provides:

  • Instant App Alerts for collision notifications
  • Live Streaming for real-time remote monitoring
  • Find My Car for effortless vehicle tracking
  • Live Route Tracking for up-to-the-minute positioning

Powered by AI Motion Detection 2.0 and dual Hall Effect Sensors, the 4K Omni precisely detects movement, while 4G connectivity (UP05 for North America, UP04 for Europe) enhances remote surveillance, ensuring peace of mind wherever you are.

Unlike conventional dash cams, the 4K Omni features a supercapacitor, ensuring high-temperature resistance and automatic video saving before power loss, making it ideal for extreme conditions. On the road, Super-Sensing ADAS provides lane departure warnings, forward collision alerts, and pedestrian detection, actively enhancing driver safety.

Designed for effortless connectivity, the 4K Omni integrates Wi-Fi 6 for high-speed transfers, 512GB expandable storage, and multi-language voice control. Combining innovation, intelligence, and reliability, the 70mai 4K Omni sets a new industry standard for dash cam technology.

TCI Biotech Announces Strong 2024 Financial Performance, Sets Sights on Global Growth in 2025

TAIPEI, March 10, 2025 /PRNewswire/ — TCI Biotech (TCI Co., Ltd.) (TWSE: 8436), a leading CDMO+ innovator in health food and skincare biotechnology, has released its consolidated financial results for the fiscal year ending December 31, 2024. The company reported steady revenue performance, strong profitability, and continued investment in innovation to drive future growth.

Executive Commentary

“Our 2024 financial performance underscores TCI Biotech’s resilience and ability to navigate market fluctuations while maintaining strong profitability,” said Vincent Lin, CEO of TCI Biotech. “We remain committed to expanding smart manufacturing, fostering strategic partnerships, and driving cutting-edge research. By strengthening our financial position, we aim to deliver sustainable growth and long-term value for our stakeholders.”

Financial Highlights

  • Revenue: NT$7.24 billion in 2024
  • Gross Profit: NT$3.18 billion, representing a gross margin of 44%
  • Operating Profit: NT$1.03 billion, maintaining a stable 14% operating margin
  • Net Profit: NT$974 million, with earnings per share (EPS) of NT$7.60
  • Dividend: NT$10 per share, reflecting solid financial performance
  • Cash and Cash Equivalents: NT$4.77 billion, ensuring strong liquidity

Key Business Developments

  • Expansion in International Markets: Sales growth in key regions, including North America, Europe, China and Asia, reinforcing TCI Biotech’s global footprint.
  • Innovation & R&D: Advances in liquid supplements and skincare, aligned with market trends. The newly established TCI Medical Consultation Panel enhances research and ensures scientific rigor.
  • Operational Efficiency: Strategic cost management and AI-enhanced production processes have contributed to maintaining profitability despite industry challenges.
  • Sustainable Growth Strategies: Continued commitment to ESG (Environmental, Social and Governance) initiatives to enhance corporate responsibility and long-term value creation.

Outlook for 2025

TCI Biotech is optimistic about its growth trajectory for 2025, focusing on balanced regional expansion, optimized production capacity, and strategic partnerships with global enterprises. With a commitment to quality, innovation, and customer-centric solutions, the company anticipates sustained momentum in revenue and profitability, reinforcing its position as a leader in biotechnology and smart manufacturing.

For more information, please visit www.tci-bio.com.

About TCI Biotech

TCI Biotech (TCI Co., Ltd.) is a global leader in CDMO+ services, specializing in the research, development, and manufacturing of health foods and cosmetics. Committed to innovation and scientific excellence, TCI delivers high-quality, clinically backed products that empower customers worldwide.

Disclaimer: This press release contains forward-looking statements based on current expectations and assumptions, which involve risks and uncertainties. Actual results may differ due to market conditions, regulatory changes, or other unforeseen factors. TCI Biotech assumes no obligation to update forward-looking statements. Investors are advised to review the full financial report and consult professional advisors before making any investment decisions.

/C O R R E C T I O N — Newmark Group, Inc./

In the news release, Newmark Report: Resilient Singapore Office Demand Backed by Steady Economic Growth, issued 06-Mar-2025 by Newmark Group, Inc. over PR Newswire, we are advised by the company that the first sentence of the release should read “Newmark has released a study on the Singapore office leasing market.” rather than “Newmark has released a study, led by its Valuation & Advisory and Leasing & Brokerage teams, on the Singapore office leasing market.” as originally issued inadvertently. The complete, corrected release follows:

Newmark Report: Resilient Singapore Office Demand Backed by Steady Economic Growth

SINGAPORE, March 7, 2025 /PRNewswire/ — Newmark has released a study on the Singapore office leasing market. The report considers broader economic factors and ongoing trends among occupiers, projecting a positive year ahead for office leasing activity and continued moderate rental growth amid limited supply and stable economic growth on the island in 2025. 

Newmark Group, Inc.
Newmark Group, Inc.

“Increasing office-using employment and declining office supply should help to better balance the market’s supply and demand over the next 12 months, supported by steady economic growth and export growth,” said Chris Carver, MRICS, MSISV, AAPI, Executive Managing Director and Head of Asia-Pacific Valuation & Advisory. “With a limited development pipeline and sustained need for high-quality office space, we anticipate that rental growth will remain positive in 2025 and occupiers will continue to focus on workplace efficiency and employee experience, driving interest for prime spaces.”

Among the key 2024 takeaways:

  • Office vacancy rose slightly to 9.4% in 2024, largely attributable to the addition of the 1.25-million-square-foot IOI Central Boulevard Towers to the office supplyi.
  • Singapore’s CBD Grade A office rents grew approximately 2% in 2024 and are projected to increase at a moderate pace of around 2% in 2025. This growth is attributed to the limited supply of new office space in the CBD and sustained demand for premium office spacesii.
  • Flight to Quality remains a key driver of office relocations, as businesses prioritize talent acquisition and retention.
  • Service sectors, such as information and communications, financial and professional services, all grew in 2024 and are projected for further growth in 2025, which should in turn drive additional office demandiii.

Read the full report here and visit https://www.nmrk.com/insights to explore more Newmark Thought Leadership.

About Newmark
Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries (“Newmark”), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark’s comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform’s global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the twelve months ended December 31, 2024, Newmark generated revenues of over $2.7 billion. As of December 31, 2024, Newmark and our business partners together operated from approximately 170 offices with more than 8,000 professionals across four continents. To learn more, visit nmrk.com or follow @newmark.

Discussion of Forward-Looking Statements about Newmark
Statements in this document regarding Newmark that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company’s business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark’s Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.

i Source: URA (Private Sector only) & Newmark Research
ii Source: URA & Newmark Research
iii Source: Ministry of Manpower (MOM)